Climate Protection: The gobally operating CDMO Vetter reduces the emissions of greenhouse gases to zero and no longer has a CO2 footprint.
The CDMO headquartered in Laupheim/Germany significantly expands cGMP manufacturing capacity at its existing U.S. site in Milford.
Rich R&D portfolio: In the first half of 2021, Boehringer Ingelheim has supplied more humans and animals worldwide with innovative medicines than ever before.
New location in Austria: CDMO Vetter has further invested in additional capacity to meet this growing global demand.
Contract development and manufacturing organization expands production of highly complex antibodies at German site.
Quantum computing in Biopharma R&D: Boehringer Ingelheim joins the Quantum Technology and Application Consortium as a founding member.
Once again, Vetter's excellence in business has been rewarded with the Axia Best Managed Companies Award.
With a sales growth of 3% and the highest R&D investment in the company's history, 2020 was a good year for Boehringer Ingelheim despite impact of COVID-19.
Ulm to become one of the sites of a new German Center for Child and Adolescent Health
Vetter opens new branch office in China: The new sales office in Shanghai is the fourth office in the Asia-Pacific region.
Vetter was granted the CMO Leadership Award 2021 in five core categories.
Rentschler Biopharma establishes Center of Excellence for cell and gene therapy in the UK, and will build new ATMP capacity at the site in Stevenage.
CureVac further strengthens its global manufacturing network: Rentschler Biopharma is responsible for manufacturing, downstream processing and formulation of CureVac's CVnCoV at its site in Laupheim.
Science Magazine has named the development of effective vaccines against COVID-19 at record speed as 2020’s top scientific achievement.
Well-Deserved Recognition: The Top Employers Institute awarded Boehringer Ingelheim as a one of the world’s 16 best employers.
Boehringer Ingelheim joins forces with Google to breake new ground in the application of quantum computing in pharmaceutical research and development.
In a pilot project involving the University and the University Hospital Tübingen, a start-up based in Ulm is testing the production of personalied drugs using digital 2D/3D printing.
Boehringer Ingelheim signs the agreement on the acquisition of all shares of Labor Dr. Merk & Kollegen to strengthen its Next Generation Cancer Immunology Program.
Boehringer Ingelheim today announced the initiation of a Phase 2 clinical trial of BI 764198, an inhibitor of TRPC6, a receptor-operated cation channel.
Vetter, a globally leading contract development and manufacturing organization (CDMO), has moved into its new headquarters in Ravensburg, Germany.
Rentschler Biopharma contributes to manufacturing of COVID-19 mRNA vaccine.
First half 2020: Minimizing the impact of the COVID-19 pandemic on its employees, patients and society are priorities for Boehringer Ingelheim.
Vetter and Rentschler Biopharma team up to simplify processes and optimize time-to-market.
Rentschler announces the signing of a commercial license agreement for the production of highly complex proteins.
Boehringer Ingelheim Biopharmaceuticals China Ltd. has been awarded with a 2020 Facility of the Year Award (FOYA) from the International Society for Pharmaceutical Engineering (ISPE).
Boehringer Ingelheim has stepped up its efforts in the fight against the COVID-19 pandemic, backed by strong business performance in previous years, including 2019.
The Biotech World as Guest at the BioPharma Cluster South Germany.
Ulm University: Among top 150 universities worldwide and Germany's top 15.